David E. Nichols - Publications

Purdue University, West Lafayette, IN, United States 
Dopamine and Serotonin Agonists

174 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE, Shoichet BK, Skiniotis G, Roth BL. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT Serotonin Receptor. Cell. 182: 1574-1588.e19. PMID 32946782 DOI: 10.1016/J.Cell.2020.08.024  0.312
2019 Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Soula A, Nutt D. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology (Oxford, England). 269881119857204. PMID 31303095 DOI: 10.1177/0269881119857204  0.424
2017 Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic Drugs in Biomedicine. Trends in Pharmacological Sciences. PMID 28947075 DOI: 10.1016/j.tips.2017.08.003  0.405
2017 Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, Stratford A, Klein LM, McCorvy JD, Nichols DE, Halberstadt AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Testing and Analysis. PMID 28585392 DOI: 10.1002/Dta.2222  0.678
2017 Hoehn RD, Nichols DE, McCorvy JD, Neven H, Kais S. Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation. Proceedings of the National Academy of Sciences of the United States of America. PMID 28500275 DOI: 10.1073/Pnas.1618422114  0.718
2017 Nichols DE. Chemistry and Structure-Activity Relationships of Psychedelics. Current Topics in Behavioral Neurosciences. PMID 28401524 DOI: 10.1007/7854_2017_475  0.346
2017 Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, Lansu K, Schools ZL, Che T, Nichols DE, Shoichet BK, Dror RO, Roth BL. Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell. 168: 377-389.e12. PMID 28129538 DOI: 10.1016/J.Cell.2016.12.033  0.71
2016 Nichols DE, Johnson MW, Nichols CD. Psychedelics as Medicines: An Emerging New Paradigm. Clinical Pharmacology and Therapeutics. PMID 28019026 DOI: 10.1002/cpt.557  0.443
2015 Nichols DE, Sassano MF, Halberstadt AL, Klein LM, Brandt SD, Elliott SP, Fiedler WJ. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. Acs Chemical Neuroscience. 6: 1165-75. PMID 25547199 DOI: 10.1021/Cn500292D  0.436
2014 Martin DA, Marona-Lewicka D, Nichols DE, Nichols CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology. 83: 1-8. PMID 24704148 DOI: 10.1016/j.neuropharm.2014.03.013  0.448
2013 Juncosa JI, Hansen M, Bonner LA, Cueva JP, Maglathlin R, McCorvy JD, Marona-Lewicka D, Lill MA, Nichols DE. Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. Acs Chemical Neuroscience. 4: 96-109. PMID 23336049 DOI: 10.1021/Cn3000668  0.834
2012 Pigott A, Frescas S, McCorvy JD, Huang XP, Roth BL, Nichols DE. trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family. Beilstein Journal of Organic Chemistry. 8: 1705-9. PMID 23209503 DOI: 10.3762/Bjoc.8.194  0.768
2012 Clark AH, McCorvy JD, Conley JM, Williams WK, Bekkam M, Watts VJ, Nichols DE. Identification of a 2-phenyl-substituted octahydrobenzo[f]quinoline as a dopamine D₃ receptor-selective full agonist ligand. Bioorganic & Medicinal Chemistry. 20: 6366-74. PMID 23018094 DOI: 10.1016/J.Bmc.2012.08.058  0.816
2012 Chemel BR, Bonner LA, Watts VJ, Nichols DE. Ligand-specific roles for transmembrane 5 serine residues in the binding and efficacy of dopamine D(1) receptor catechol agonists. Molecular Pharmacology. 81: 729-38. PMID 22334593 DOI: 10.1124/Mol.111.077339  0.849
2012 McCorvy JD, Watts VJ, Nichols DE. Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease. Psychopharmacology. 222: 81-7. PMID 22222862 DOI: 10.1007/S00213-011-2625-5  0.721
2012 Halberstadt AL, Nichols DE, Geyer MA. Behavioral effects of α,α,β,β-tetradeutero-5-MeO-DMT in rats: comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology. 221: 709-18. PMID 22222861 DOI: 10.1007/S00213-011-2616-6  0.353
2012 Cueva JP, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines. European Journal of Medicinal Chemistry. 48: 97-107. PMID 22204903 DOI: 10.1016/J.Ejmech.2011.11.039  0.84
2011 Clark AH, McCorvy JD, Watts VJ, Nichols DE. Assessment of dopamine D₁ receptor affinity and efficacy of three tetracyclic conformationally-restricted analogs of SKF38393. Bioorganic & Medicinal Chemistry. 19: 5420-31. PMID 21862338 DOI: 10.1016/J.Bmc.2011.07.057  0.836
2011 McCorvy JD, Harland AA, Maglathlin R, Nichols DE. A 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference. Neuroscience Letters. 505: 10-3. PMID 21827831 DOI: 10.1016/J.Neulet.2011.07.036  0.729
2011 Marona-Lewicka D, Nichols DE. Potential serotonin 5-HT(1A) and dopamine D(4) receptor modulation of the discriminative stimulus effects of amphetamine in rats. Behavioural Pharmacology. 22: 508-15. PMID 21814134 DOI: 10.1097/FBP.0b013e328349fc31  0.488
2011 Cueva JP, Gallardo-Godoy A, Juncosa JI, Vidi PA, Lill MA, Watts VJ, Nichols DE. Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues. Journal of Medicinal Chemistry. 54: 5508-21. PMID 21714510 DOI: 10.1021/Jm200334C  0.813
2011 Bonner LA, Laban U, Chemel BR, Juncosa JI, Lill MA, Watts VJ, Nichols DE. Mapping the catechol binding site in dopamine D₁ receptors: synthesis and evaluation of two parallel series of bicyclic dopamine analogues. Chemmedchem. 6: 1024-40. PMID 21538900 DOI: 10.1002/Cmdc.201100010  0.814
2011 Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology. 61: 503-12. PMID 21352832 DOI: 10.1016/j.neuropharm.2011.02.006  0.571
2011 Clark LH, Cueva JP, McCorvy JD, Harland AA, Watts VJ, Nichols DE. C-Ring expanded analogs of doxanthrine: Conformation plays a critical role Arkivoc. 2010: 125-138. DOI: 10.3998/Ark.5550190.0011.411  0.849
2010 Bonner LA, Chemel BR, Watts VJ, Nichols DE. Facile synthesis of octahydrobenzo[h]isoquinolines: novel and highly potent D1 dopamine agonists. Bioorganic & Medicinal Chemistry. 18: 6763-70. PMID 20709559 DOI: 10.1016/J.Bmc.2010.07.052  0.84
2010 Laban U, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE. ChemInform Abstract: A Novel Fluorinated Tryptamine with Highly Potent Serotonin 5-HT1A Receptor Agonist Properties. Cheminform. 32: no-no. DOI: 10.1002/chin.200127116  0.84
2010 VANGVERAVONG S, NICHOLS DE. ChemInform Abstract: Stereoselective Synthesis of trans-2-(Indol-3-yl)cyclopropylamines: Rigid Tryptamine Analogues. Cheminform. 26: no-no. DOI: 10.1002/CHIN.199545041  0.665
2009 Trachsel D, Nichols DE, Kidd S, Hadorn M, Baumberger F. 4-aryl-substituted 2,5-dimethoxyphenethylamines: synthesis and serotonin 5-HT(2A) receptor affinities. Chemistry & Biodiversity. 6: 692-704. PMID 19479848 DOI: 10.1002/cbdv.200800235  0.536
2009 Marona-Lewicka D, Nichols DE. WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D(4) receptor activation. Behavioural Pharmacology. 20: 114-8. PMID 19179855 DOI: 10.1097/FBP.0b013e3283242f1a  0.486
2009 Przybyla JA, Cueva JP, Chemel BR, Hsu KJ, Riese DJ, McCorvy JD, Chester JA, Nichols DE, Watts VJ. Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 19: 138-46. PMID 19028082 DOI: 10.1016/J.Euroneuro.2008.10.002  0.834
2009 Marona-Lewicka D, Chemel BR, Nichols DE. Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology. 203: 265-77. PMID 18604600 DOI: 10.1007/S00213-008-1238-0  0.827
2009 Cueva JP, Nichols DE. A novel and efficient synthesis of dihydrexidine Synthesis. 715-720. DOI: 10.1055/S-0028-1083359  0.756
2008 Torres-Altoro MI, White KJ, Rodríguez GJ, Nichols DE, Barker EL. Helix XI contributes to the entrance of the serotonin transporter permeation pathway. Protein Science : a Publication of the Protein Society. 17: 1761-70. PMID 18628241 DOI: 10.1110/Ps.036749.108  0.313
2008 Nichols DE, Nichols CD. Serotonin receptors. Chemical Reviews. 108: 1614-41. PMID 18476671 DOI: 10.1021/cr078224o  0.604
2008 Nichols DE, Frescas SP, Chemel BR, Rehder KS, Zhong D, Lewin AH. High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorganic & Medicinal Chemistry. 16: 6116-23. PMID 18468904 DOI: 10.1016/J.Bmc.2008.04.050  0.827
2008 Schultz DM, Prescher JA, Kidd S, Marona-Lewicka D, Nichols DE, Monte A. 'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorganic & Medicinal Chemistry. 16: 6242-51. PMID 18467103 DOI: 10.1016/J.Bmc.2008.04.030  0.511
2008 Walline CC, Nichols DE, Carroll FI, Barker EL. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. The Journal of Pharmacology and Experimental Therapeutics. 325: 791-800. PMID 18354055 DOI: 10.1124/jpet.108.136200  0.37
2008 Parker MA, Kurrasch DM, Nichols DE. The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorganic & Medicinal Chemistry. 16: 4661-9. PMID 18296055 DOI: 10.1016/j.bmc.2008.02.033  0.483
2007 Braden MR, Nichols DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Molecular Pharmacology. 72: 1200-9. PMID 17715398 DOI: 10.1124/Mol.107.039255  0.817
2007 Marona-Lewicka D, Nichols DE. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacology, Biochemistry, and Behavior. 87: 453-61. PMID 17618679 DOI: 10.1016/j.pbb.2007.06.001  0.498
2007 Mu Q, Johnson K, Morgan PS, Grenesko EL, Molnar CE, Anderson B, Nahas Z, Kozel FA, Kose S, Knable M, Fernandes P, Nichols DE, Mailman RB, George MS. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophrenia Research. 94: 332-41. PMID 17596915 DOI: 10.1016/J.Schres.2007.03.033  0.39
2007 George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, Nahas Z, Knable M, Fernandes P, Juncos J, Huang X, Nichols DE, Mailman RB. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophrenia Research. 93: 42-50. PMID 17467956 DOI: 10.1016/J.Schres.2007.03.011  0.323
2007 Selken J, Nichols DE. Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacology, Biochemistry, and Behavior. 86: 622-30. PMID 17363047 DOI: 10.1016/j.pbb.2007.02.006  0.369
2007 Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB. Functional selectivity and classical concepts of quantitative pharmacology. The Journal of Pharmacology and Experimental Therapeutics. 320: 1-13. PMID 16803859 DOI: 10.1124/Jpet.106.104463  0.451
2006 Cueva JP, Giorgioni G, Grubbs RA, Chemel BR, Watts VJ, Nichols DE. trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist. Journal of Medicinal Chemistry. 49: 6848-57. PMID 17154515 DOI: 10.1021/Jm0604979  0.831
2006 Parrish JC, Nichols DE. Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. Journal of Neurochemistry. 99: 1164-75. PMID 17010161 DOI: 10.1111/J.1471-4159.2006.04173.X  0.798
2006 White KJ, Kiser PD, Nichols DE, Barker EL. Engineered zinc-binding sites confirm proximity and orientation of transmembrane helices I and III in the human serotonin transporter. Protein Science : a Publication of the Protein Society. 15: 2411-22. PMID 17008722 DOI: 10.1110/Ps.062386106  0.327
2006 Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology. 70: 1956-64. PMID 17000863 DOI: 10.1124/Mol.106.028720  0.844
2006 McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. Journal of Medicinal Chemistry. 49: 5794-803. PMID 16970404 DOI: 10.1021/Jm060656O  0.854
2006 Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology. 188: 244-51. PMID 16915381 DOI: 10.1007/S00213-006-0490-4  0.857
2006 McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE. C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. Journal of Medicinal Chemistry. 49: 4269-74. PMID 16821786 DOI: 10.1021/Jm060272Y  0.831
2006 Lewis MM, Huang X, Nichols DE, Mailman RB. D1 and functionally selective dopamine agonists as neuroprotective agents in Parkinson's disease. Cns & Neurological Disorders Drug Targets. 5: 345-53. PMID 16787233 DOI: 10.2174/187152706777452245  0.318
2005 Parrish JC, Braden MR, Gundy E, Nichols DE. Differential phospholipase C activation by phenylalkylamine serotonin 5-HT 2A receptor agonists. Journal of Neurochemistry. 95: 1575-84. PMID 16277614 DOI: 10.1111/J.1471-4159.2005.03477.X  0.845
2005 Ryman-Rasmussen JP, Nichols DE, Mailman RB. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Molecular Pharmacology. 68: 1039-48. PMID 15985612 DOI: 10.1124/mol.105.012153  0.567
2005 Gallardo-Godoy A, Fierro A, McLean TH, Castillo M, Cassels BK, Reyes-Parada M, Nichols DE. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. Journal of Medicinal Chemistry. 48: 2407-19. PMID 15801832 DOI: 10.1021/jm0493109  0.372
2005 Marona-Lewicka D, Thisted RA, Nichols DE. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology. 180: 427-35. PMID 15723230 DOI: 10.1007/s00213-005-2183-9  0.419
2004 Hrometz SL, Brown AW, Nichols DE, Sprague JE. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neuroscience Letters. 367: 56-9. PMID 15308297 DOI: 10.1016/J.Neulet.2004.05.075  0.353
2004 Gay EA, Urban JD, Nichols DE, Oxford GS, Mailman RB. Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states. Molecular Pharmacology. 66: 97-105. PMID 15213300 DOI: 10.1124/Mol.66.1.97  0.482
2004 Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE. 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms. Bioorganic & Medicinal Chemistry. 12: 1403-12. PMID 15018913 DOI: 10.1016/J.Bmc.2004.01.008  0.841
2004 Nichols DE. Hallucinogens. Pharmacology & Therapeutics. 101: 131-81. PMID 14761703 DOI: 10.1016/j.pharmthera.2003.11.002  0.339
2004 Sit SY, Xie K, Jacutin-Porte S, Boy KM, Seanz J, Taber MT, Gulwadi AG, Korpinen CD, Burris KD, Molski TF, Ryan E, Xu C, Verdoorn T, Johnson G, Nichols DE, et al. Synthesis and SAR exploration of dinapsoline analogues. Bioorganic & Medicinal Chemistry. 12: 715-34. PMID 14759732 DOI: 10.1016/j.bmc.2003.11.015  0.524
2004 Marona-Lewicka D, Nichols DE. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology. 172: 415-21. PMID 14647959 DOI: 10.1007/s00213-003-1677-6  0.544
2004 Roman DL, Saldaña SN, Nichols DE, Carroll FI, Barker EL. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. The Journal of Pharmacology and Experimental Therapeutics. 308: 679-87. PMID 14593087 DOI: 10.1124/Jpet.103.057836  0.407
2004 Nichols DE, Lewis MM. Mechanisms and issues relating to the use of D1-like dopamine receptor agonists for age-related illnesses: Parkinson's disease and memory and cognition Medicinal Chemistry Research. 13: 105-114. DOI: 10.1007/s00044-004-0016-8  0.38
2003 Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. Journal of Neurochemistry. 86: 980-91. PMID 12887695 DOI: 10.1046/J.1471-4159.2003.01921.X  0.823
2003 Chambers JJ, Parrish JC, Jensen NH, Kurrasch-Orbaugh DM, Marona-Lewicka D, Nichols DE. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands. Journal of Medicinal Chemistry. 46: 3526-35. PMID 12877591 DOI: 10.1021/Jm030064V  0.837
2003 Rodríguez GJ, Roman DL, White KJ, Nichols DE, Barker EL. Distinct recognition of substrates by the human and Drosophila serotonin transporters. The Journal of Pharmacology and Experimental Therapeutics. 306: 338-46. PMID 12682215 DOI: 10.1124/Jpet.103.048751  0.36
2003 Qandil AM, Lewis MM, Jassen A, Leonard SK, Mailman RB, Nichols DE. Synthesis and pharmacological evaluation of substituted naphth[1,2,3-de]isoquinolines (dinapsoline analogues) as D1 and D2 dopamine receptor ligands. Bioorganic & Medicinal Chemistry. 11: 1451-64. PMID 12628671 DOI: 10.1016/S0968-0896(02)00561-8  0.48
2003 Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. The Journal of Pharmacology and Experimental Therapeutics. 304: 229-37. PMID 12490596 DOI: 10.1124/Jpet.102.042184  0.837
2002 Chambers JJ, Nichols DE. A homology-based model of the human 5-HT2A receptor derived from an in silico activated G-protein coupled receptor. Journal of Computer-Aided Molecular Design. 16: 511-20. PMID 12510883 DOI: 10.1023/A:1021275430021  0.697
2002 Kanthasamy A, Sprague JE, Shotwell JR, Nichols DE. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience. 114: 917-24. PMID 12379247 DOI: 10.1016/S0306-4522(02)00368-8  0.608
2002 Marona-Lewicka D, Kurrasch-Orbaugh DM, Selken JR, Cumbay MG, Lisnicchia JG, Nichols DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats. Psychopharmacology. 164: 93-107. PMID 12373423 DOI: 10.1007/S00213-002-1141-Z  0.84
2002 Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD). Journal of Medicinal Chemistry. 45: 4344-9. PMID 12213075 DOI: 10.1021/Jm020153S  0.813
2002 Falk EM, Cook VJ, Nichols DE, Sprague JE. An antisense oligonucleotide targeted at MAO-B attenuates rat striatal serotonergic neurotoxicity induced by MDMA. Pharmacology, Biochemistry, and Behavior. 72: 617-22. PMID 12175458 DOI: 10.1016/S0091-3057(02)00728-1  0.353
2002 Whiteside MS, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE, Monte A. Substituted hexahydrobenzodipyrans as 5-HT2A/2C receptor probes. Bioorganic & Medicinal Chemistry. 10: 3301-6. PMID 12150876 DOI: 10.1016/S0968-0896(02)00209-2  0.835
2002 Chambers JJ, Kurrasch-Orbaugh DM, Nichols DE. Translocation of the 5-alkoxy substituent of 2,5-dialkoxyarylalkylamines to the 6-position: effects on 5-HT(2A/2C) receptor affinity. Bioorganic & Medicinal Chemistry Letters. 12: 1997-9. PMID 12113827 DOI: 10.1016/S0960-894X(02)00306-2  0.832
2002 Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS, O'Malley KL, Todd RD, Blake BL, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. The Journal of Pharmacology and Experimental Therapeutics. 301: 1179-89. PMID 12023553 DOI: 10.1124/jpet.301.3.1179  0.524
2002 Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 301: 1166-78. PMID 12023552 DOI: 10.1124/jpet.301.3.1166  0.547
2002 Sprague JE, Leifheit M, Selken J, Milks MM, Kinder DH, Nichols DE. In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse (New York, N.Y.). 43: 118-21. PMID 11754490 DOI: 10.1002/Syn.10025  0.309
2001 Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. International Review of Neurobiology. 48: 65-139. PMID 11526741 DOI: 10.1016/S0074-7742(01)48014-7  0.527
2001 Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists. Journal of Medicinal Chemistry. 44: 1003-10. PMID 11300881 DOI: 10.1021/Jm000491Y  0.853
2001 Laban U, Kurrasch-Orbaugh D, Marona-Lewicka D, Nichols DE. A novel fluorinated tryptamine with highly potent serotonin 5-HT1A receptor agonist properties. Bioorganic & Medicinal Chemistry Letters. 11: 793-5. PMID 11277522 DOI: 10.1016/S0960-894X(01)00062-2  0.824
2001 Sattelkau T, Qandil AM, Nichols DE. An efficient synthesis of the potent dopamine D1 agonist dinapsoline by construction and selective reduction of 2′-azadimethoxybenzanthrone Synthesis. 262-266. DOI: 10.1055/S-2001-10809  0.452
2001 Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. ChemInform Abstract: Effect of Ring Fluorination on the Pharmacology of Hallucinogenic Tryptamines. Cheminform. 32: no-no. DOI: 10.1002/chin.200111113  0.762
2000 Blair JB, Kurrasch-Orbaugh D, Marona-Lewicka D, Cumbay MG, Watts VJ, Barker EL, Nichols DE. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. Journal of Medicinal Chemistry. 43: 4701-10. PMID 11101361 DOI: 10.1021/Jm000339W  0.833
1999 Gerasimov M, Marona-Lewicka D, Kurrasch-Orbaugh DM, Qandil AM, Nichols DE. Further studies on oxygenated tryptamines with LSD-like activity incorporating a chiral pyrrolidine moiety into the side chain. Journal of Medicinal Chemistry. 42: 4257-63. PMID 10514296 DOI: 10.1021/Jm990325U  0.842
1999 Hoffman B, Cho SJ, Zheng W, Wyrick S, Nichols DE, Mailman RB, Tropsha A. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods. Journal of Medicinal Chemistry. 42: 3217-26. PMID 10464009 DOI: 10.1021/jm980415j  0.367
1999 Blair JB, Marona-Lewicka D, Kanthasamy A, Lucaites VL, Nelson DL, Nichols DE. Thieno[3,2-b]- and thieno[2,3-b]pyrrole bioisosteric analogues of the hallucinogen and serotonin agonist N,N-dimethyltryptamine. Journal of Medicinal Chemistry. 42: 1106-11. PMID 10090793 DOI: 10.1021/Jm980692Q  0.7
1999 Doll MK, Nichols DE, Kilts JD, Prioleau C, Lawler CP, Lewis MM, Mailman RB. Synthesis and dopaminergic properties of benzo-fused analogues of quinpirole and quinelorane. Journal of Medicinal Chemistry. 42: 935-40. PMID 10072690 DOI: 10.1021/jm9804533  0.562
1999 Qandil AM, Ghosh D, Nichols DE. Alternative formal synthesis of the potent D1 dopamine agonist dihydroxy-2,3,7,11b-tetrahydro-1H-naphth[1,2,3-de]isoquinoline: Dinapsoline Journal of Organic Chemistry. 64: 1407-1409. DOI: 10.1021/jo982067z  0.441
1998 Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT2A receptor. Journal of Medicinal Chemistry. 41: 5148-9. PMID 9857084 DOI: 10.1021/Jm9803525  0.476
1998 Vangveravong S, Kanthasamy A, Lucaites VL, Nelson DL, Nichols DE. Synthesis and serotonin receptor affinities of a series of trans-2-(indol-3-yl)cyclopropylamine derivatives. Journal of Medicinal Chemistry. 41: 4995-5001. PMID 9836617 DOI: 10.1021/Jm980318Q  0.837
1998 Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biological Psychiatry. 44: 1099-117. PMID 9836014 DOI: 10.1016/S0006-3223(98)00187-5  0.395
1998 Troconis M, Ma W, Nichols DE, McLaughlin J. Molecular modeling study of tubulosine and other related ipecac alkaloids. Journal of Computer-Aided Molecular Design. 12: 411-8. PMID 9834903 DOI: 10.1023/A:1008019720578  0.38
1998 Lewis MM, Watts VJ, Lawler CP, Nichols DE, Mailman RB. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. The Journal of Pharmacology and Experimental Therapeutics. 286: 345-53. PMID 9655879  0.468
1998 Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE. Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity. Journal of Medicinal Chemistry. 41: 2134-45. PMID 9622555 DOI: 10.1021/jm980076u  0.56
1998 Cozzi NV, Frescas S, Marona-Lewicka D, Huang X, Nichols DE. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacology, Biochemistry, and Behavior. 59: 709-15. PMID 9512076 DOI: 10.1016/S0091-3057(97)00557-1  0.388
1997 Monte AP, Waldman SR, Marona-Lewicka D, Wainscott DB, Nelson DL, Sanders-Bush E, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. Journal of Medicinal Chemistry. 40: 2997-3008. PMID 9301661 DOI: 10.1021/jm970219x  0.526
1997 Negash K, Nichols DE, Watts VJ, Mailman RB. Further definition of the D1 dopamine receptor pharmacophore: synthesis of trans-6,6a,7,8,9,13b-hexahydro-5H-benzo[d]naphth[2,1-b]azepines as rigid analogues of beta-phenyldopamine. Journal of Medicinal Chemistry. 40: 2140-7. PMID 9216832 DOI: 10.1021/Jm970157A  0.441
1997 Smith HP, Nichols DE, Mailman RB, Lawler CP. Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. European Journal of Pharmacology. 323: 27-36. PMID 9105873 DOI: 10.1016/S0014-2999(97)00026-5  0.514
1996 Reyes-Parada M, Scorza C, Romero V, Silveira R, Medina JH, Andrus D, Nichols DE, Cassels BK. (+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 354: 579-85. PMID 8938655 DOI: 10.1007/Bf00170831  0.456
1996 Sprague JE, Johnson MP, Schmidt CJ, Nichols DE. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochemical Pharmacology. 52: 1271-7. PMID 8937435 DOI: 10.1016/0006-2952(96)00482-0  0.355
1996 Cozzi NV, Nichols DE. 5-HT2A receptor antagonists inhibit potassium-stimulated gamma-aminobutyric acid release in rat frontal cortex. European Journal of Pharmacology. 309: 25-31. PMID 8864689 DOI: 10.1016/0014-2999(96)00325-1  0.363
1996 Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacology, Biochemistry, and Behavior. 53: 99-105. PMID 8848466 DOI: 10.1016/0091-3057(95)00205-7  0.324
1996 Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. Journal of Medicinal Chemistry. 39: 2953-61. PMID 8709129 DOI: 10.1021/jm960199j  0.522
1996 Mottola DM, Laiter S, Watts VJ, Tropsha A, Wyrick SD, Nichols DE, Mailman RB. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. Journal of Medicinal Chemistry. 39: 285-96. PMID 8568818 DOI: 10.1021/Jm9502100  0.564
1996 Ghosh D, Snyder SE, Watts VJ, Mailman RB, Nichols DE. 9-Dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: a potent full dopamine D1 agonist containing a rigid-beta-phenyldopamine pharmacophore. Journal of Medicinal Chemistry. 39: 549-55. PMID 8558526 DOI: 10.1021/Jm950707+  0.46
1995 Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. Psychostimulant-like effects of p-fluoroamphetamine in the rat. European Journal of Pharmacology. 287: 105-13. PMID 8749023 DOI: 10.1016/0014-2999(95)00478-5  0.376
1995 Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, Mailman RB. Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse (New York, N.Y.). 21: 177-87. PMID 8584979 DOI: 10.1002/syn.890210211  0.542
1995 Brewster WK, Nichols DE, Watts VJ, Riggs RM, Mottola D, Mailman RB. Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine receptor ligands. Journal of Medicinal Chemistry. 38: 318-27. PMID 7830274 DOI: 10.1021/Jm00002A013  0.851
1995 Heidenreich BA, Mailman RB, Nichols DE, Napier TC. Partial and full dopamine D1 agonists produce comparable increases in ventral pallidal neuronal activity: contribution of endogenous dopamine. The Journal of Pharmacology and Experimental Therapeutics. 273: 516-25. PMID 7714807  0.328
1995 Monte AP, Marona-Lewicka D, Kanthasamy A, Sanders-Bush E, Nichols DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. Journal of Medicinal Chemistry. 38: 958-66. PMID 7699712 DOI: 10.1021/Jm00006A015  0.637
1995 Knoerzer TA, Watts VJ, Nichols DE, Mailman RB. Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors. Journal of Medicinal Chemistry. 38: 3062-70. PMID 7636869 DOI: 10.1021/Jm00016A009  0.431
1995 Snyder SE, Aviles-Garay FA, Chakraborti R, Nichols DE, Watts VJ, Mailman RB. Synthesis and evaluation of 6,7-dihydroxy-2,3,4,8,9,13b-hexahydro-1H- benzo[6,7]cyclohepta[1,2,3-ef][3]benzazepine, 6,7-dihydroxy- 1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(aminomethyl)-9,10- dihydro-1,2-dihydroxyanthracene as conformationally restricted analogs of beta-phenyldopamine. Journal of Medicinal Chemistry. 38: 2395-409. PMID 7608904 DOI: 10.1021/Jm00013A015  0.517
1995 Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology. 118: 401-9. PMID 7568626 DOI: 10.1007/Bf02245940  0.576
1995 Gilmore JH, Watts VJ, Lawler CP, Noll EP, Nichols DE, Mailman RB. "Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications. Neuropharmacology. 34: 481-8. PMID 7566481 DOI: 10.1016/0028-3908(95)00014-W  0.538
1995 Sprague JE, Nichols DE. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology. 118: 357-9. PMID 7542394 DOI: 10.1007/Bf02245967  0.373
1995 Vangveravong S, Nichols DE. Stereoselective synthesis of trans-2-(indol-3-yl)cyclopropylamines: Rigid tryptamine analogues Journal of Organic Chemistry. 60: 3409-3413. DOI: 10.1021/Jo00116A028  0.682
1994 Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF. 1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist. Journal of Medicinal Chemistry. 37: 4346-51. PMID 7996545 DOI: 10.1021/Jm00051A011  0.535
1994 Minor DL, Wyrick SD, Charifson PS, Watts VJ, Nichols DE, Mailman RB. Synthesis and molecular modeling of 1-phenyl-1,2,3,4-tetrahydroisoquinolines and related 5,6,8,9-tetrahydro-13bH-dibenzo[a,h]quinolizines as D1 dopamine antagonists. Journal of Medicinal Chemistry. 37: 4317-28. PMID 7996543 DOI: 10.1021/Jm00051A008  0.525
1994 Sprague JE, Huang X, Kanthasamy A, Nichols DE. Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sciences. 55: 1193-8. PMID 7934616 DOI: 10.1016/0024-3205(94)00658-X  0.612
1994 Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola D, Mailman RB. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. Journal of Medicinal Chemistry. 37: 2453-60. PMID 7914538 DOI: 10.1021/Jm00041A025  0.852
1994 Lewis MH, Gariépy JL, Gendreau P, Nichols DE, Mailman RB. Social reactivity and D1 dopamine receptors: studies in mice selectively bred for high and low levels of aggression. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 10: 115-22. PMID 7912934 DOI: 10.1038/npp.1994.13  0.37
1994 Nash JF, Roth BL, Brodkin JD, Nichols DE, Gudelsky GA. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neuroscience Letters. 177: 111-5. PMID 7824160 DOI: 10.1016/0304-3940(94)90057-4  0.486
1993 Watts VJ, Lawler CP, Knoerzer T, Mayleben MA, Neve KA, Nichols DE, Mailman RB. Hexahydrobenzo[a]phenanthridines: novel dopamine D3 receptor ligands. European Journal of Pharmacology. 239: 271-3. PMID 8223910 DOI: 10.1016/0014-2999(93)91012-C  0.549
1993 Kohli JD, Horn PT, Glock D, Brewster WK, Nichols DE. Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. European Journal of Pharmacology. 235: 31-5. PMID 8100195 DOI: 10.1016/0014-2999(93)90816-Z  0.846
1993 Watts VJ, Lawler CP, Gilmore JH, Southerland SB, Nichols DE, Mailman RB. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. European Journal of Pharmacology. 242: 165-72. PMID 7902811 DOI: 10.1016/0014-2999(93)90076-T  0.5
1993 Callaway CW, Wing LL, Nichols DE, Geyer MA. Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology. 111: 169-78. PMID 7870948 DOI: 10.1007/BF02245519  0.393
1992 Tomaszewski Z, Johnson MP, Huang X, Nichols DE. Benzofuran bioisosteres of hallucinogenic tryptamines. Journal of Medicinal Chemistry. 35: 2061-4. PMID 1534585  0.433
1992 Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. The Journal of Pharmacology and Experimental Therapeutics. 262: 383-93. PMID 1352553  0.415
1991 Nichols DE, Snyder SE, Oberlender R, Johnson MP, Huang XM. 2,3-Dihydrobenzofuran analogues of hallucinogenic phenethylamines. Journal of Medicinal Chemistry. 34: 276-81. PMID 1992127 DOI: 10.1021/JM00105A043  0.387
1991 Callaway CW, Johnson MP, Gold LH, Nichols DE, Geyer MA. Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists. Psychopharmacology. 104: 293-301. PMID 1924637 DOI: 10.1007/BF02246026  0.391
1991 Huang XM, Johnson MP, Nichols DE. Reduction in brain serotonin markers by alpha-ethyltryptamine (Monase). European Journal of Pharmacology. 200: 187-90. PMID 1722753 DOI: 10.1016/0014-2999(91)90686-K  0.337
1991 Lovenberg TW, Roth RH, Nichols DE, Mailman RB. D1 dopamine receptors of NS20Y neuroblastoma cells are functionally similar to rat striatal D1 receptors. Journal of Neurochemistry. 57: 1563-9. PMID 1717649 DOI: 10.1111/J.1471-4159.1991.Tb06352.X  0.411
1991 Elsworth JD, Lawrence MS, Roth RH, Taylor JR, Mailman RB, Nichols DE, Lewis MH, Redmond DE. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. The Journal of Pharmacology and Experimental Therapeutics. 259: 595-600. PMID 1682479  0.348
1991 Lovenberg TW, Nichols DE, Nestler EJ, Roth RH, Mailman RB. Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors. Brain Research. 556: 101-7. PMID 1682005 DOI: 10.1016/0006-8993(91)90552-7  0.392
1991 Taylor JR, Lawrence MS, Redmond DE, Elsworth JD, Roth RH, Nichols DE, Mailman RB. Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys. European Journal of Pharmacology. 199: 389-91. PMID 1680717 DOI: 10.1016/0014-2999(91)90508-N  0.401
1991 Steele TD, Brewster WK, Johnson MP, Nichols DE, Yim GK. Assessment of the role of alpha-methylepinine in the neurotoxicity of MDMA. Pharmacology, Biochemistry, and Behavior. 38: 345-51. PMID 1676172 DOI: 10.1016/0091-3057(91)90289-E  0.77
1990 Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman RB. trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. Journal of Medicinal Chemistry. 33: 1756-64. PMID 1971308 DOI: 10.1021/Jm00168A034  0.853
1990 Nichols DE, Brewster WK, Johnson MP, Oberlender R, Riggs RM. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). Journal of Medicinal Chemistry. 33: 703-10. PMID 1967651 DOI: 10.1021/Jm00164A037  0.803
1990 Kohli JD, Glock D, Brewster WK, Knoerzer T, Nichols DE. A new potent and selective DA1 (vascular) dopamine receptor agonist European Journal of Pharmacology. 183: 1287. DOI: 10.1016/0014-2999(90)94395-E  0.831
1989 Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. European Journal of Pharmacology. 166: 111-3. PMID 2572425 DOI: 10.1016/0014-2999(89)90690-0  0.846
1988 Nichols DE, Lloyd DH, Johnson MP, Hoffman AJ. Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors. Journal of Medicinal Chemistry. 31: 1406-12. PMID 3385733 DOI: 10.1021/Jm00402A026  0.505
1987 Johnson MP, Hoffman AJ, Nichols DE, Mathis CA. Binding to the serotonin 5-HT2 receptor by the enantiomers of 125I-DOI. Neuropharmacology. 26: 1803-6. PMID 3437942 DOI: 10.1016/0028-3908(87)90138-9  0.493
1987 Riggs RM, McKenzie AT, Byrn SR, Nichols DE, Foreman MM, Truex LL. Effect of beta-alkyl substitution on D-1 dopamine agonist activity: absolute configuration of beta-methyldopamine. Journal of Medicinal Chemistry. 30: 1914-8. PMID 3309317 DOI: 10.1021/Jm00393A039  0.324
1986 Nichols DE. Studies of the relationship between molecular structure and hallucinogenic activity. Pharmacology, Biochemistry, and Behavior. 24: 335-40. PMID 3952123 DOI: 10.1016/0091-3057(86)90362-X  0.356
1986 Nichols DE, Hoffman AJ, Oberlender RA, Riggs RM. Synthesis and evaluation of 2,3-dihydrobenzofuran analogues of the hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane: drug discrimination studies in rats. Journal of Medicinal Chemistry. 29: 302-4. PMID 3950910 DOI: 10.1021/Jm00152A022  0.376
1986 Hoffman AJ, Maxwell DM, Nichols DE. A simple organ bath for electrical stimulation and superfusion of rat brain slices. Journal of Pharmacological Methods. 16: 185-99. PMID 3784567 DOI: 10.1016/0160-5402(86)90041-0  0.31
1986 Johnson MP, Hoffman AJ, Nichols DE. Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. European Journal of Pharmacology. 132: 269-76. PMID 2880735 DOI: 10.1016/0014-2999(86)90615-1  0.385
1985 Hoffman AJ, Nichols DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Journal of Medicinal Chemistry. 28: 1252-5. PMID 4032428 DOI: 10.1021/Jm00147A022  0.353
1984 Nichols DE, Jadhav KP, Oberlender RA, Zabik JE, Bossart JF, Hamada A, Miller DD. Synthesis and evaluation of substituted 2-phenylcyclobutylamines as analogues of hallucinogenic phenethylamines: lack of LSD-like biological activity. Journal of Medicinal Chemistry. 27: 1108-11. PMID 6471065 DOI: 10.1002/Chin.198505188  0.321
1978 Nichols DE, Weintraub HJ, Pfister WR, Yim GK. The use of rigid analogues to probe hallucinogen receptors. Nida Research Monograph. 70-83. PMID 101889  0.325
1977 Nichols DE, Shulgin AT, Dyer DC. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sciences. 21: 569-75. PMID 904435 DOI: 10.1016/0024-3205(77)90099-6  0.401
1977 Nichols DE, Dyer DC. Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues. Journal of Medicinal Chemistry. 20: 299-301. PMID 836502 DOI: 10.1021/Jm00212A022  0.43
1976 Nichols DE. Structural correlation between apomorphine and LSD: involvement of dopamine as well as serotonin in the actions of hallucinogens. Journal of Theoretical Biology. 59: 167-77. PMID 7711 DOI: 10.1016/S0022-5193(76)80030-6  0.449
1975 Barfknecht CF, Nichols DE. Correlation of psychotomimetic activity of phenethylamines and amphetamines with 1-octanol-water partition coefficients. Journal of Medicinal Chemistry. 18: 208-10. PMID 1120990 DOI: 10.1002/Chin.197525187  0.602
1975 Ilhan M, Nichols DE, Long JP, Cannon JG. Apomorphine-like effect of an aminotetralin on the linguomandibular reflex of the cat. European Journal of Pharmacology. 33: 61-4. PMID 240731 DOI: 10.1016/0014-2999(75)90138-7  0.508
1974 Cheng HC, Long JP, Nichols DE, Barfknecht CF, Rusterholz DB. Effects of rigid amphetamine analogs on vascular strips: studies of 2-aminotetrahydronaphthalene and 2-aminoindan derivatives. Archives Internationales De Pharmacodynamie Et De ThéRapie. 208: 264-73. PMID 4851775  0.579
1974 Cheng HC, Long JP, Nichols DE, Barfknecht CF. Effects of psychotomimetics on vascular strips: studies of methoxylated amphetamines and optical isomers of 2,5-dimethoxy-4-methylamphetamine and 2,5-dimethoxy-4-bromoamphetamine. The Journal of Pharmacology and Experimental Therapeutics. 188: 114-23. PMID 4809263  0.553
1974 Nichols DE, Barfknecht CF, Long JP, Standridge RT, Howell HG, Partyka RA, Dyer DC. Potential psychotomimetics. 2. Rigid analogs of 2,5-dimethoxy-4-methylphenylisopropylamine (DOM, STP). Journal of Medicinal Chemistry. 17: 161-6. PMID 4809251 DOI: 10.1021/Jm00248A004  0.608
1974 Cheng HC, Long JP, Nichols DE, Barfknecht CF. Effects of para-methoxyamphetamine (PMA) on the cardiovascular system of the dog. Archives Internationales De Pharmacodynamie Et De ThéRapie. 212: 83-8. PMID 4455128  0.536
1973 Dyer DC, Nichols DE, Rusterholz DB, Barfknecht CF. Comparative effects of stereoisomers of psychotomimetic phenylisopropylamines. Life Sciences. 13: 885-96. PMID 4766265 DOI: 10.1016/0024-3205(73)90079-9  0.631
1973 Barfknecht CF, Nichols DE, Rusterholz DB, Long JP, Engelbrecht JA, Beaton JM, Bradley RJ, Dyer DC. Potential psychotomimetics. 2-Amino-1,2,3,4-tetrahydronaphthalene analogs. Journal of Medicinal Chemistry. 16: 804-8. PMID 4725926 DOI: 10.1002/Chin.197342259  0.595
1973 Cheng HC, Long JP, Barfknecht CF, Nichols DE. Cardiovascular effects of 2, 5-dimethoxy-4-methylamphetamine (DOM, STP). The Journal of Pharmacology and Experimental Therapeutics. 186: 345-54. PMID 4719787  0.541
1973 Nichols DE, Barfknecht CF, Rusterholz DB, Benington F, Morin RD. Asymmetric synthesis of psychotomimetic phenylisopropylamines. Journal of Medicinal Chemistry. 16: 480-3. PMID 4718460 DOI: 10.1021/Jm00263A013  0.608
1973 Nichols DE, Barfknecht CF. 1-Methyl-3-piperidone and 1-methyl-3-pyrrolidone derivatives from a dieckmann reaction Journal of Heterocyclic Chemistry. 10: 339-341. DOI: 10.1002/Jhet.5570100311  0.557
1973 NICHOLS DE, BARFKNECHT CF. ChemInform Abstract: 1-METHYL-3-PIPERIDONE AND 1-METHYL-3-PYRROLIDONE DERIVATIVES FROM A DIECKMANN REACTION Chemischer Informationsdienst. 4: no-no. DOI: 10.1002/chin.197345340  0.546
1972 Engelbrecht JA, Long JP, Nichols DE, Barfknecht CF. Pharmacologic evaluation of 3,4-dimethoxyphenylpropenes and 3,4-dimethoxyphenylpropanediols. Archives Internationales De Pharmacodynamie Et De ThéRapie. 199: 226-44. PMID 5070643  0.556
1972 Barfknecht CF, Nichols DE. Effects of S-(+)- and R-(-)-3,4,dimethoxyphenylisopropylamines in the rat. Journal of Medicinal Chemistry. 15: 109-10. PMID 5007083 DOI: 10.1021/Jm00271A037  0.594
1971 Barfknecht CF, Nichols DE. Potential psychotomimetics. Bromomethoxyamphetamines. Journal of Medicinal Chemistry. 14: 370-2. PMID 5553756 DOI: 10.1021/Jm00286A026  0.575
1971 Antun F, Smythies JR, Benington F, Morin RD, Barfknecht CF, Nichols DE. Native fluorescence and hallucinogenic potency of some amphetamines. Experientia. 27: 62-3. PMID 5549244 DOI: 10.1007/BF02137743  0.561
1971 Barfknecht CF, Smith RV, Nichols DE, Leseney JL, Long JP, Engelbrecht JA. Chemistry and pharmacological evaluation of 1-phenyl-2-propanols and 1-phenyl-2-propanones. Journal of Pharmaceutical Sciences. 60: 799-801. PMID 5125790 DOI: 10.1002/Jps.2600600533  0.598
1971 BARFKNECHT CF, SMITH RV, NICHOLS DE, LESENEY JL, LONG JP, ENGELBRECHT JA. ChemInform Abstract: CHEMIE UND PHARMAKOLOGISCHE BEWERTUNG VON 1-PHENYLPROPANOLEN-(2)(I) UND 1-PHENYLPROPANONEN-(2)(II) Chemischer Informationsdienst. Organische Chemie. 2: no-no. DOI: 10.1002/Chin.197136272  0.525
Show low-probability matches.